Cecchini, M., Cruz-Correa, M., Han, S.-W., Raghav, K., Magdalena, A. L., Strickler, J. H., … Sharma, M. R. (2025). 731MO Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Dose expansion results of a phase I study. In Annals of Oncology (Vol. 36, pp. S511–S512). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.1306

Cecchini, M., M. Cruz-Correa, S. -. W. Han, K. Raghav, A Landa Magdalena, J. H. Strickler, PA Calvo Ferrandiz, et al. “731MO Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Dose expansion results of a phase I study.” In Annals of Oncology, 36:S511–12. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.1306.

Cecchini M, Cruz-Correa M, Han S-W, Raghav K, Magdalena AL, Strickler JH, et al. 731MO Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Dose expansion results of a phase I study. In: Annals of Oncology. Elsevier BV; 2025. p. S511–2.

Cecchini, M., et al. “731MO Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Dose expansion results of a phase I study.” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S511–12. Crossref, doi:10.1016/j.annonc.2025.08.1306.

Cecchini M, Cruz-Correa M, Han S-W, Raghav K, Magdalena AL, Strickler JH, Ferrandiz PAC, Hollebecque A, Nakajima TE, Perl G, Jain VK, Hunter Z, Burns M, Blaney ME, Li RR, Vasilopoulos A, Alshaer M, Sharma MR. 731MO Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Dose expansion results of a phase I study. Annals of Oncology. Elsevier BV; 2025. p. S511–S512.